Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2023: Latest in mRCC

Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald

ASCO 2023: Latest in mRCC ( Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald )

Pembrolizumab improves OS in firstline treatment for unresectable advanced...

Dr Penelope Bradbury - Princess Margaret Cancer Centre, Toronto, Canada

Pembrolizumab improves OS in firstline treatment for unresectable advanced pleural mesothelioma ( Dr Penelope Bradbury - Princess Margaret Cancer Centre, Toronto, Canada )

Pembro plus chemo followed by resection and adjuvant pembro improves on...

Prof Heather Wakelee - Stanford Cancer Institute, Stanford, USA

Pembro plus chemo followed by resection and adjuvant pembro improves on standard of care for early NSCLC ( Prof Heather Wakelee - Stanford Cancer Institute, Stanford, USA )

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in...

Prof Adam Sperling - Dana-Farber Cancer Institute, Boston, USA

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in phase 1 ( Prof Adam Sperling - Dana-Farber Cancer Institute, Boston, USA )

Teclistamab plus talquetamab targeting BCMA and GPRC5D shows promise in RRMM

Dr Yael Cohen - Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Teclistamab plus talquetamab targeting BCMA and GPRC5D shows promise in RRMM ( Dr Yael Cohen - Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel )

Talquetamab plus daratumumab for RRMM: TRIMM-2 update

Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville...

Talquetamab plus daratumumab for RRMM: TRIMM-2 update ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment...

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

The current status of multiple myeloma diagnosis and treatment

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

The current status of multiple myeloma diagnosis and treatment ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

Choosing cancer medicines wisely in Africa

Dr Harrison Chuwa - Aga Khan Hospital, Dar es Salaam, Tanzania

Choosing cancer medicines wisely in Africa ( Dr Harrison Chuwa - Aga Khan Hospital, Dar es Salaam, Tanzania )

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru

Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma...

Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence ( Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA )

More from ecancer